CAR-T疗法在卵巢癌中的应用前景

doi:10.11904/j.issn.1002-3070.2021.01.012

摘要/Abstract

摘要： 卵巢癌是最致命的妇科肿瘤,由于其发病潜伏期长,缺乏早期诊断手段,导致大多数患者初治时已是晚期。除了常规的手术化疗外,近年来,嵌合抗原受体修饰的T细胞(CAR-T)在肿瘤系统治疗的研究领域中受到相当大的关注。各种临床前实验和临床试验已证实了CAR-T细胞免疫疗法是卵巢癌的一种有前景的治疗方法,并显示出有别于其他实体瘤的优势,但是仍需要面对诸多挑战。在这篇综述中,我们将系统的讲述CAR-T细胞免疫疗法的最新研究进展,包括CAR-T细胞疗法的生物学理解、临床应用、所面对的挑战及可能改善治疗效果的策略。

关键词: 卵巢癌, CAR-T细胞治疗, 基因编辑技术, 细胞因子释放综合征, 靶上-肿瘤外毒性

Abstract: Ovarian cancer(OC)is the most deadly gynecological tumor.Because of its long onset latency and lack of early diagnosis,most patients are already in advanced stage at the time of initial treatment.In addition to the conventional surgical chemotherapy,in recent years,chimeric antigen receptor modified T cells(CAR-T)have received considerable attention in the research field of tumor system therapy.Various preclinical experiments and clinical trials have confirmed that CAR-T cell immunotherapy is a promising treatment for OC,and it shows the advantages that are different from other solid tumors,but it still needs to face many challenges.In this review,we will systematically introduce the latest research progress of CAR-T cell immunotherapy,including the biological understanding of CAR-T cell therapy,clinical application,challenges faced and possible strategies to improve the therapeutic effect.

Key words: Ovarian cancer, CAR-T cell therapy, Gene editing technology, Cytokine release syndrome, On-target-extratumor toxicity

中图分类号:

R737.31

张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.

ZHANG Wenwen,JIANG Liangliang,WANG Jing. Application prospect of CAR-T therapy in ovarian cancer[J]. Journal of Practical Oncology, 2021, 35(1): 59-63.

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Rizzuto I,Stavraka C,Chatterjee J,et al.Risk of ovarian cancer relapse score:aprognostic algorithm to predict relapse following treatment for advanced ovarian cancer[J].Int J Gynecol Cancer,2015,25(3):416-22.
3 Batlevi CL,Matsuki E,Brentjens RJ,et al.Novel immunotherapies in lymphoid malignancies[J].Nat Rev Clin Oncol,2016,13(1):25-40.
4 Wang Z,Chen W,Zhang X,et al.A long way to the battlefront:CAR T cell therapy against solid cancers[J].J Cancer,2019,10(14):3112-3123.
5 Baumeister SH,Murad J,Werner L,et al.Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma[J].Cancer Immunol Res,2019,7(1):100-112.
6Brown CE,Aguilar B,Starr R,et al.Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved persistence and antitumor efficacy against glioblastoma[J].Mol Ther,2018,26(1):31-44.
7 Harris DT,Kranz DM,Adoptive T.Cell therapies:a comparison of T cell receptors and chimeric antigen receptors[J].Trends Pharmacol Sci,2015,37(3):220-230.
8 Xu X,Qiu J,Sun Y.The basics of CAR-T design and challenges in immunotherapy of solid tumors ovarian cancer as a model[J].Hun Vaccin Immunother,2017,13(7):1548-1555.
9 Gross G,Waks T,Eshhar Z,et al.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proc Natl Acad Sci U S A,1989,86(24):10024-10028.
10 Kawalekar OU,O'connor RS,Fraietta JA,et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR-T cells[J].Immunity,2016,44(2):380-390.
11 Hay KA,Turtle CJ.Chimeric antigen receptor(CAR)T cells:lessons learned from targeting of CD19 in B-cell malignancies[J].Drugs,2017,77(3):237-245.
12 Zhang Q,Zhang Z,Peng M,et al.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma:from bench to bedside[J].OncoImmunology,2016,5(12):e1251539.
13 Chen N,Li X,Chintala NK,et al.Driving CARs on the uneven road of antigen heterogeneity in solid tumors[J].Curr Opin Immunol,2018,51:103-110.
14 Ebert LM,Yu W,Gargett T,et al.Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology[J].Biochem Soc T,2018,46(2):391-401.
15 Annesley CE,Summers C,Ceppi F,et al.The evolution and future of CART cells for B-cell acute lymphoblastic leukemia[J].Clin Pharmacol Ther,2018,103(4):591-598.
16 Mauro C,Keisuke W,June CH,et al.Driving cars to the clinic for solid tumors[J].Gene Ther,2018,25(3):165-175.
17 Westwood JA,Smyth MJ,Teng MW,et al.Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice[J].Proc Natl Acad Sci U S A,2005,102(52):19051-19056.
18 Jamali A,Kapitza L,Schaser T,et al.Highly efficient and selective CAR-gene transfer using CD4-and CD8-targeted lentiviral vectors[J].Mol Ther Methods Clin Dev,2019,13:371-379.
19 Wu H,Wang K,Liu W,et al.Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo[J].Genet Mol Res,2015,14(2):6591-6597.
20 Kim CK,Haider KH,Choi SH,et al.Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells[J].Gynecol Oncol,2002,84(1):85-93.
21 Wiesinger M,Mrz J,Kummer M,et al.Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance[J].Cancers(Basel),2019,11(8):2072-2094.
22 Hudecek M,Izsvák Z,Johnen S,et al.Going non-viral:the sleeping beauty transposon system breaks on through to the clinical side[J].Crit Rev Biochem Mol Biol,2017,52(4):355-380.
23 Sapranauskas R,Gasiunas G,Fremaux C,et al.The streptococcus thermophilus CRISPR/Cas system provides immunity in escherichia coli[J].Nucl Acids Res,2011,39(21):9275-9282.
24 Charpentier E,Doudna JA.Biotechnology:rewriting a genome[J].Nature,2013,495(7439):50-51.
25 Adli M.The CRISPR tool kit for genome editing and beyond[J]. Nat Commun,2018,9(1):1911.
26 Eyquem J,Mansilla-Soto J,Giavridis T,et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J].Nature,2017,543(7643):113-117.
27 Roth TL,Puig-Saus C,Yu R,et al.Reprogramming human T cell function and specificity with non-viral genome targeting[J].Nature,2018,559(7714):405-409.
28 Seki A,Rutz S.Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells[J].J Exp Med,2018,215(3):985-997.
29 Cho SW,Kim S,Kim Y,et al.Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases[J].Genome Res,2014,24(1):132-141.
30 Salas-Mckee J,Kong W,Gladney WL,et al.CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy[J].Hum Vaccin Immunother,2019,15(5):1126-1132.
31 Zhu X,Cai H,Zhao L,et al.CAR-T cell therapy in ovarian cancer:from the bench to the bedside[J].Oncotarget,2017,8(38):64607-64621.
32 Owens GL,Sheard VE,Kalaitsidou M,et al.Preclinical assessment of CAR T-Cell therapy targeting the tumor antigen 5T4 in ovarian cancer[J].J Immunother,2018,41(3):130-140.
33 Hwu P,Shafer GE,Treisman J,et al.Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the fc receptor gamma chain[J].J Exp Med,1993,178(1):361-366.
34 Chatterjee M,Mohapatra S,Ionan A,et al.Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays[J].Cancer Res,2006,66(2):1181-1190.
35 Rodriguez-Garcia A,Sharma P,Poussin M,et al.CAR T-cells targeting müllerian inhibiting substance type 2 receptor for the treatment of ovarian cancer and other gynecologic malignancies[J].Mol Ther,2020,28(2):548-560.
36 Coelho R,Marcos-Silva L,Ricardo S,et al.Peritoneal dissemination of ovarian cancer:role of MUC16-mesothelin interaction and implications for treatment[J].Expert Rev Anticancer Ther,2018,18(2):177-186.
37 Santoro SP,Kim S,Motz GT,et al.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression[J].Cancer Immunol Res,2015,3(1):68-84.
38 John PM,Anna KK,Hee JL,et al.Effective targeting of TAG72+peritoneal ovarian tumors via regional delivery of CAR-engineered T cells[J].Front Immunol,2018,9:2268.
39 Tanyi JL,Stashwick C,Plesa G,et al.Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T Cells[J].J Immunother,2017,40(3):104-107.
40 Whilding LM,Halim L,Draper B,et al.CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies[J].Cancers(Basel),2019,11(5):674.
41 Drent E,Themeli M,Poels R,et al.A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization[J].Mol Ther,2017,25(8):1946-1958.
42 Caruso HG,Hurton LV,Najjar A,et al.Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J].Cancer Res,2015,75(17):3505-3518.
43 Jensen MC,Riddell SR.Designing chimeric antigen receptors to effectively and safely target tumors.[J].Curr Opin Immunol,2015,33:9-15.
44 Roybal KT,Rupp LJ,Morsut L,et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits[J].Cell,2016,164(4):770-779.
45 Deng C,Zhao J,Zhou S,et al.The vascular disrupting agent CA4P improve the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors[J].Mol Ther,2020,28(1):75-88.
46 Coon ME,Stephan SB,Gupta V,et al.Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours[J].Nat Biomed Eng,2020,4(2):195-206.
47 Gargett T,Yu W,Dotti G,et al.GD2-specific CAR-T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade[J].Mol Ther,2016,24(6):1135-1149.
48 Ma L,Dichwalkar T,Chang JYH,et al.Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor[J].Science,2019,365(6449):162-168.

[1]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[2]	梁永琴, 赵宏伟. 抗血管生成药物在铂耐药卵巢癌中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 60-63.
[3]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[4]	邓明新, 张颖. 环状RNA与卵巢癌研究新进展[J]. 实用肿瘤学杂志, 2019, 33(6): 549-552.
[5]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[6]	宋玲, 付琼. 紫云英苷通过上调PHD2抑制缺氧诱导的卵巢癌细胞增殖和侵袭[J]. 实用肿瘤学杂志, 2019, 33(5): 407-414.
[7]	张蓓蕾, 李怡, 吴涛, 姜锋, 赵宏喜, 李艳红. 血根碱通过诱导细胞凋亡抑制卵巢癌肿瘤生长的机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 305-309.
[8]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.
[9]	宋玲, 付琼. 紫云英苷通过抑制HIF-1α诱导的糖酵解途径发挥抗卵巢肿细胞作用的研究[J]. 实用肿瘤学杂志, 2018, 32(6): 503-509.
[10]	姜亮亮综述, 王晶审校. 上皮性卵巢癌远处转移的诊治进展[J]. 实用肿瘤学杂志, 2018, 32(5): 480-482.
[11]	梁冠盈, 迟秋君, 李晓梅. 伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 298-302.
[12]	李文辉, 吕博文, 钱钧, 苏丽菊, 杨桐树, 钱景荣, 王杰. MicroRNA-150对上皮性卵巢癌细胞增殖、凋亡和侵袭转移能力的影响[J]. 实用肿瘤学杂志, 2018, 32(3): 208-213.
[13]	毕琦玲, 周立红, 韩毅敏. HOX基因与妇科肿瘤的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 140-143.
[14]	陈丹, 李加桩, 隋红. 阿帕替尼多重癌1例附文献回顾[J]. 实用肿瘤学杂志, 2017, 31(5): 441-443.
[15]	于歌, 孙佳宁, 冯晓玲. 上皮性卵巢肿瘤组织中PSMD10、Ki67的表达及其临床病理意义[J]. 实用肿瘤学杂志, 2017, 31(2): 112-116.